KEYNOTE-006: a success in melanoma, but a long way to go
Mené dans 16 pays sur 834 patients atteints d'un mélanome non résécable et de stade avancé, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, du pembrolizumab et de l'ipilimumab (durée médiane de suivi : 22,9 mois)
A breakthrough in cancer therapy was achieved by the introduction of immune checkpoint inhibition, starting with the US Food and Drug Administration approval of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)-specific antibody ipilimumab in 2011.1,2 Since then, clinical experience indicates that only around 20% of patients with late-stage melanoma experience durable responses with ipilimumab, but can pay a high price in terms of adverse events, because ipilimumab has been associated with autoimmune reactions like colitis that can require treatment discontinuation.
The Lancet , commentaire, 2016